Real-world study: FF/UMEC/VI step-up therapy for COPD comparatively more advantageous than BUD/GLY/FORM
Stepping up to triple therapy with inhaled corticosteroid (ICS) plus a long-acting muscarinic antagonist (LAMA) and a long-acting β2-agonist (LABA) is recommended for patients with chronic obstructive pulmonary disease (COPD) inadequately controlled with dual therapy. The use of single-inhaler therapy has also been recommended over the use of multiple inhalers, as convenience has been associated with better treatment adherence and effectiveness. This article highlights the results of the first real-world comparative effectiveness study of two single-inhaler triple therapy (SITT) formulations, fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) and budesonide/ glycopyrrolate/formoterol fumarate (BUD/GLY/FORM), in patients who stepped up from prior dual combination therapy.
